Pharvaris BV (PHVS) earnings

Healthcare · Biotechnology · Market cap $2.0B

In the quarter ended June 2025, Pharvaris BV had revenue of —, and diluted EPS of -0.83.

On August 12, 2026 it reported EPS of -0.81 against an estimate of -0.74 (missed).

The next report is expected on Wednesday, November 11, 2026, with EPS expected around -0.82.

Report dates

ReportDateTimeEPS estimateEPS reported
NextWed Nov 11, 2026 — -0.82 —
LastWed Aug 12, 2026 — -0.74 -0.81

Dates from company announcements and exchange calendars; estimates are the consensus where available. See the full earnings calendar.

Quarterly results

The last 5 quarters from Pharvaris BV's 10-Q and 10-K filings with the SEC, in EUR. Growth is against the same quarter a year earlier. EPS here is GAAP diluted EPS as filed; the reported EPS compared with estimates above can be on the company's adjusted basis, so the two can differ.

Quarter endedRevenueGrowthEPS (diluted)GrowthOp. marginFiled
Jun 30, 2025— — -0.83 — — 2025-08-12
Jun 30, 2024— — -0.55 — — 2024-08-14
Jun 30, 2023— — -0.63 — — 2023-08-07
Jun 30, 2022— — -0.38 — — 2022-09-12
Jun 30, 2021— — -0.46 — — 2022-09-12
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for PHVS.
Open PHVS in Investingly

Questions

When does Pharvaris BV report earnings?

Pharvaris BV's next earnings report is expected on November 11, 2026.

How did Pharvaris BV do last quarter?

In the quarter ended June 2025, Pharvaris BV had revenue of —, and diluted EPS of -0.83.

From Pharvaris BV's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.